JP2020526520A5 - - Google Patents
Info
- Publication number
- JP2020526520A5 JP2020526520A5 JP2020500206A JP2020500206A JP2020526520A5 JP 2020526520 A5 JP2020526520 A5 JP 2020526520A5 JP 2020500206 A JP2020500206 A JP 2020500206A JP 2020500206 A JP2020500206 A JP 2020500206A JP 2020526520 A5 JP2020526520 A5 JP 2020526520A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- free base
- fluoroquinoline
- cyclohexyl
- chlorophenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762527855P | 2017-06-30 | 2017-06-30 | |
| US62/527,855 | 2017-06-30 | ||
| PCT/US2018/040262 WO2019006283A1 (en) | 2017-06-30 | 2018-06-29 | AMORPHOUS AND CRYSTALLINE FORMS OF IDO INHIBITORS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020526520A JP2020526520A (ja) | 2020-08-31 |
| JP2020526520A5 true JP2020526520A5 (https=) | 2025-03-14 |
| JP7690284B2 JP7690284B2 (ja) | 2025-06-10 |
Family
ID=64742242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020500206A Active JP7690284B2 (ja) | 2017-06-30 | 2018-06-29 | Ｉｄｏ阻害剤の非晶質形態および結晶形態 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11236049B2 (https=) |
| EP (1) | EP3644993B1 (https=) |
| JP (1) | JP7690284B2 (https=) |
| KR (1) | KR102630575B1 (https=) |
| CN (1) | CN111093651B (https=) |
| AU (1) | AU2018294314B2 (https=) |
| CA (1) | CA3066789A1 (https=) |
| EA (1) | EA202090119A1 (https=) |
| IL (1) | IL271601B2 (https=) |
| MX (2) | MX391848B (https=) |
| SG (1) | SG11201911937UA (https=) |
| WO (1) | WO2019006283A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7315483B2 (ja) * | 2017-06-30 | 2023-07-26 | ブリストル－マイヤーズ スクイブ カンパニー | 置換キノリニルシクロヘキシルプロパンアミド化合物および改良されたその製造方法 |
| EP4426022A3 (en) * | 2017-11-17 | 2024-11-20 | Telefonaktiebolaget LM Ericsson (publ) | Signaling ta-offset in nr |
| CN110357813A (zh) * | 2018-04-09 | 2019-10-22 | 信达生物制药(苏州)有限公司 | 一种新型吲哚胺2,3-双加氧酶抑制剂及其制备方法和用途 |
| WO2020000236A1 (zh) * | 2018-06-27 | 2020-01-02 | 深圳仁泰医药科技有限公司 | (r)-n-(4-氯苯基)-2-(顺-4-(6-氟喹啉-4-基)环己基)丙酰胺的晶型 |
| WO2021050653A1 (en) * | 2019-09-11 | 2021-03-18 | Bristol-Myers Squibb Company | Pharmaceutical formulations of indoleamine 2, 3-dioxygenase inhibitors |
| BR112022009944A2 (pt) * | 2019-11-26 | 2022-08-09 | Bristol Myers Squibb Co | Sais / cocristais de (r)-n-(4-clorofenil)-2-((1s,4s)-4-(6-fluoroquinolin-4-il)ciclo-hexil)propanamida |
| AR120935A1 (es) * | 2020-01-02 | 2022-03-30 | Hutchison Medipharma Ltd | Derivados de amida y usos de los mismos |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6627646B2 (en) * | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| PT2343320T (pt) | 2005-03-25 | 2018-01-23 | Gitr Inc | Anticorpos anti-gitr e as suas utilizações |
| PL1879573T3 (pl) | 2005-05-10 | 2013-05-31 | Incyte Holdings Corp | Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| US8450351B2 (en) | 2005-12-20 | 2013-05-28 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| WO2008036642A2 (en) | 2006-09-19 | 2008-03-27 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| US8591886B2 (en) | 2007-07-12 | 2013-11-26 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| US10047066B2 (en) | 2007-11-30 | 2018-08-14 | Newlink Genetics Corporation | IDO inhibitors |
| WO2009156652A1 (fr) | 2008-05-29 | 2009-12-30 | Saint-Gobain Centre De Recherches Et D'etudes Europeen | Structure en nid d'abeille a base de titanate d'aluminium |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| KR101790802B1 (ko) | 2009-09-03 | 2017-10-27 | 머크 샤프 앤드 돔 코포레이션 | 항-ｇｉｔｒ 항체 |
| EP2493862B1 (en) | 2009-10-28 | 2016-10-05 | Newlink Genetics Corporation | Imidazole derivatives as ido inhibitors |
| ES2722300T3 (es) | 2009-12-10 | 2019-08-09 | Hoffmann La Roche | Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso |
| EP2542256B1 (en) | 2010-03-04 | 2019-05-22 | MacroGenics, Inc. | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| US9169323B2 (en) | 2010-03-05 | 2015-10-27 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
| JP5989547B2 (ja) | 2010-03-05 | 2016-09-07 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒトｃｓｆ−１ｒに対する抗体及びその使用 |
| HRP20190047T1 (hr) | 2010-05-04 | 2019-02-22 | Five Prime Therapeutics, Inc. | Protutijela koja se vežu na csf1r |
| MX337040B (es) | 2010-09-09 | 2016-02-09 | Pfizer | Moleculas de union a 4-1bb. |
| NO2694640T3 (https=) | 2011-04-15 | 2018-03-17 | ||
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| RU2658603C2 (ru) | 2011-12-15 | 2018-06-21 | Ф.Хоффманн-Ля Рош Аг | Антитела против человеческого csf-1r и их применения |
| KR20140127855A (ko) | 2012-02-06 | 2014-11-04 | 제넨테크, 인크. | Csf1r 억제제를 사용하는 조성물 및 방법 |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| RU2670743C9 (ru) | 2012-05-11 | 2018-12-19 | Файв Прайм Терапьютикс, Инк. | Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r) |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| UY36390A (es) * | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen |
| UY36391A (es) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen |
| JP7315483B2 (ja) | 2017-06-30 | 2023-07-26 | ブリストル－マイヤーズ スクイブ カンパニー | 置換キノリニルシクロヘキシルプロパンアミド化合物および改良されたその製造方法 |
-
2018
- 2018-06-29 EP EP18823337.3A patent/EP3644993B1/en active Active
- 2018-06-29 WO PCT/US2018/040262 patent/WO2019006283A1/en not_active Ceased
- 2018-06-29 EA EA202090119A patent/EA202090119A1/ru unknown
- 2018-06-29 KR KR1020207002491A patent/KR102630575B1/ko active Active
- 2018-06-29 CA CA3066789A patent/CA3066789A1/en active Pending
- 2018-06-29 CN CN201880044036.6A patent/CN111093651B/zh active Active
- 2018-06-29 SG SG11201911937UA patent/SG11201911937UA/en unknown
- 2018-06-29 IL IL271601A patent/IL271601B2/en unknown
- 2018-06-29 AU AU2018294314A patent/AU2018294314B2/en active Active
- 2018-06-29 JP JP2020500206A patent/JP7690284B2/ja active Active
- 2018-06-29 US US16/624,490 patent/US11236049B2/en active Active
- 2018-06-29 MX MX2019014885A patent/MX391848B/es unknown
-
2019
- 2019-12-10 MX MX2021015656A patent/MX2021015656A/es unknown
-
2021
- 2021-12-16 US US17/553,434 patent/US12421195B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7690284B2 (ja) | Ｉｄｏ阻害剤の非晶質形態および結晶形態 | |
| JP2020526520A5 (https=) | ||
| US11104682B2 (en) | Salts of TAM inhibitors | |
| TW202114680A (zh) | Ｈｐｋ１抑制劑之固體形式 | |
| WO2023122777A1 (en) | Oxime derivatives useful as t cell activators | |
| JP2021535182A (ja) | ホスホイノシチド３−キナーゼ（ｐｉ３ｋ）阻害剤の結晶形態 | |
| TW202023562A (zh) | 喹唑啉化合物及其鹽酸鹽之結晶形態 | |
| WO2024263853A1 (en) | Substituted oxoisoindolinyl piperidine-2,6-dione compound as anticancer agent | |
| AU2024285766A1 (en) | Spirocyclic substituted oxoisoindolinyl piperidine-2,6-dione compound | |
| KR20250019700A (ko) | 치환된 페닐 옥사졸론 화합물 | |
| US12527783B2 (en) | Salts/cocrystals of (R)-N-(4-chlorophenyl-2-((1S,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide | |
| EA041037B1 (ru) | Аморфные и кристаллические формы ido-ингибиторов | |
| EA049146B1 (ru) | Аморфные и кристаллические формы ido-ингибиторов | |
| BR112019027259B1 (pt) | Formas amorfas e cristalinas de inibidores da ido, seus usos, e composição farmacêutica | |
| HK40127606A (zh) | 经取代的苯基恶唑酮化合物 |